Abstract: Cyclophosphamide (CP) treatment is associated with the risk of haemorrhagic cystitis (HC). Moreover, CP-induced HC is complicated by autonomic nervous system (ANS) dysfunction. Pemirolast is thought to be a mast cell stabiliser that inhibits the release of many inflammatory mediators and sensory neuropeptides, and thus, it may be considered a potential chemoprotective HC agent. The aim of the study was to indirectly estimate the effect of pemirolast in experimental HC by measuring ANS activity with the heart rate variability (HRV) method. In CP-treated rats, we found a decreasing trend of overall autonomic activity, together with an imbalance between the main components, and a dominant very low frequency (VLF) power component. Pemirolast treatment did not improve the total HRV power value or the main non-normalized HRV components. Moreover, CP-HC animals treated with pemirolast displayed a different disproportion of normalized spectral components as compared to both control and CP-HC animals without pemirolast treatment, with the balance between normalized low frequency (nLF) and normalized high frequency (nHF) shifted towards nLF. This finding, together with a relatively high VLF tension, indicates that the pemirolast treatment resulted in high sympathetic activity that may contribute to HC exacerbation; thus, this agent seems to be ineffective in CP-induced HC.
Introduction
Oxazaphosphorines are classified as belonging to the group of cytotoxic alkylating agents with a broad spectrum of antitumor activity in humans. The group of oxazaphosphorines contains cyclophosphamide (CP) and other agents, including ifosfamide (IF), trofosfamide, sufosfamide, and mafosfamide [1, 2] .
Ross et al. [3] more than 60 years ago formulated the concept that the cytotoxic action of alkylating agents is based on the alkylation of nucleophilic centres of biomolecules, such as the N7 position of guanine in DNA. Thus, the intracellular release of alkylating agents leads to the inhibition of DNA polymerase and specific DNA alkylation by covalent bonding, with subsequent depletion of DNA polymerisation ("suicidal inactivation") [1, [4] [5] [6] .
Both CP and ifosfamide produce multiple adverse drug reactions (ADR), including disturbances originating from almost all systems and resulting in hematologic, gastrointestinal, genitourinary, dermatologic, respiratory, endocrine, and neurological drug-evoked abnormalities. Among various side effects, haemorrhagic cystitis, as a genitourinary oxazaphosphorine-related adverse reaction, seems to be one of the most important. Symptoms of HC overlap with those associated with overactive bladder, including irritative voiding, increase in urinary frequency, dysuria, urgency, incontinence, and nocturia [7, 8] . In clinical practice, development of HC as a result of CP or ifosfamide treatment was reported to be as high as approximately 70%. Life-threatening HC with uncontrolled haemorrhage is estimated at approximately 4% [9] .
Pathophysiological mechanisms underlying HC are complex, because they are a consequence of the development of inflammation initially induced by acrolein release and subsequently by pro-inflammatory cytokines, reactive oxygen species, and nitric oxide overproduction. As a result, damage to the integrity of cells and tissues occurs, manifesting as histological and morphological abnormalities, such as swelling, bleeding, and ulcerations. [9] One of our reviews provides a more detailed pathophysiological description of HC development, as well as the mechanism of action of oxazaphosphorines [10] . Moreover, HC pathogenesis is augmented by the development of concurrent neurogenic inflammation, defined as the inflammatory responses mediated by the neuropeptides released from small-diameter, capsaicinsensitive, sensory C fibers [11] .
HC development is also reflected by abnormal activity of the autonomic nervous system (ANS), estimated by the heart rate variability (HRV) method. In our previous study [12] , we revealed that CP produced ANS functional disturbances in both high doses (200 mg/ kg body weight; single dose) and low doses (75 mg/kg body weight; four doses). We demonstrated a power decrease in all standard spectral HRV components. Single CP administration was mostly associated with a very low frequency (VLF) power reduction; whereas, chronic CP treatment was accompanied by a low (LF) and high frequency (HF) decrease [12] .
The rationale behind ongoing studies that are focused on finding new agents and preventing, or at least diminishing, HC symptoms takes into consideration the pathophysiological description of HC and its clinical consequences. It is possible to modify oxazaphosphorine-related cystitis with anti-inflammatory and antihistaminic agents widely used in pharmacology. Although histamine is not the main compound responsible for HC development, it may be considered to belong to such a group of substances, stored inside both immune cells and newly synthesized pro-inflammatory factors. Moreover, for the past 20 years it has been commonly accepted that histamine plays an essential role in the development of neurogenic inflammation [13, 14] . Thus, histaminic mechanisms contributing to HC pathogenesis may also be a potential pharmacological target. Accordingly, we have decided to estimate the influence of pemirolast potassium, one of the antihistaminics, on the bladder inflammatory response to cyclophosphamide. Pemirolast (PEM) is classified as an "atypical" antihistaminic, exerting potent anti-allergenic activity. A Medline database review shows that this agent was considered to be a new, oral, nonbronchodilator medication, demonstrating sufficient anti-asthmatic activity at a dose of 50 mg/day [15] . The studies showed various aspects of pemirolast pharmacological action. This drug is a mast cell stabiliser; thus, it inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from mast cells. Additionally, pemirolast prevents the activation of eosinophils, reduces leukotrienes, and releases eosinophil cationic proteins [16] . In general, pemirolast is a histamine H1 antagonist that, once released, competes with histamine for the H1 receptor binding site on effector cells or blood vessels. Reports have also demonstrated markedly suppressed formation of 1,2-diacylglycerol, phosphatidylinositol and phosphatic acid, suggesting the inhibition of phospholipase C activity after pemirolast administration. The coexisting blockade of phospholipase A2 has also been suggested by the decrease in release of agonists-induced arachidonic acid [17] . In addition, Itoh et al. [18] revealed that pemirolast reduced the paclitaxel-induced rise in proteins (substance P, neurokinin A and B, calcitonin gene related peptide) released from sensory peptides in rat bronchoalveolar fluid. Thus, for the first time, Itoh et al. [18] showed that pemirolast attenuates the hypersensitivity response by inhibiting the release of sensory nerve peptides. Clinically, the same scientific team reconfirmed the prophylactic effect of pemirolast against paclitaxel-induced, neurogenic-based inflammation, in their study of the influence of pemirolast in patients with ovarian cancer treated with paclitaxel [19] .
In conclusion, the influence of pemirolast on HC pathophysiology is promising. In view of our previous findings that demonstrated the autonomic dysfunction in oxazaphosphorine-induced cystitis, we aimed to estimate the ANS functioning in a cyclophosphamideinduced HC experimental model in rats treated with pemirolast. Our hypothesis was based on the assumption that the potential improvement in autonomic abnormalities after pemirolast administration is associated with parallel attenuation in bladder inflammation. The autonomic activity assessment was based on the HRV analysis, which is currently regarded as the best noninvasive method of indirect ANS assessment.
Materials and Methods

General experimental design
The aim of our study was to estimate the effect of pemirolast treatment on autonomic nervous system activity by calculating heart rate variability in rats with experimental cystitis. We performed our experiment based on the commonly used animal model of haemorrhagic cystitis induced by four doses of cyclophosphamide.
Animals
Our study comprised three groups: the control group (1) and CP-treated animals subdivided into those without pemirolast treatment (CP-HC; group 2) and those with concurrent pemirolast treatment (CP-HC+PEM; group 3).
Treatment and applied research procedures
We administrated saline (group 1), CP (group 2) or CP+PEM (group 3) intraperitoneally 4 times on every third day during the week (1st, 3rd, 5th and 7th day). The other experimental conditions were the same in all groups. Next, we carried out cutaneous electrocardiographic (ECG) recordings with subsequent HRV analysis in both time and spectral (frequency) domains, calculating standard parameters, on the 8th day after vehicle/drug administration. HRV signal was recorded for 20 minutes in resting conditions under urethane anaesthesia. Finally, after HRV recordings and an overdose of anaesthetic agent, the animals were dissected, and their bladders removed for the purposes of macroscopic and microscopic assessment. Moreover, to assure the presence of CPevoked lesions, bladder wet weight was measured, as this parameter also reflects inflammatory changes in the bladder. The calculated HRV parameters, expressed as mean ± standard deviation, were compared in all groups to ascertain the autonomic activity. These values were converted into natural logarithmic values before statistical analysis, because original HRV parameters do not have a normal distribution. Statistical analysis was performed with use of the parametric Fischer-Snedecor test with α=0.05 with paired groups (control/CP-HC, control/ CP-HC+PEM, CP-HC/CP-HC+PEM). Additionally, in all rats we compared initial and final body weight and bladder wet weight, together with the ratio of bladder wet weight to final body weight.
Statistical Methods and Experimental Procedures
Ethics
The study protocol was approved by the First Local Ethic Committee in Cracow (Decision no. 126/2010).
Animals and study groups
The animals were obtained from the central laboratory.
Rats were allowed an acclimatization period of 2 weeks in groups of five per cage upon their arrival at the animal house of the Pathophysiology Department. The animals were housed at room temperature with a day-night cycle of 12-12 hours, standard food (Labofeed, Kcynia), and ad libitum water. During the third week, the principal period of the experiment, all animals were given highenergy food to minimize the unfavourable effects of administered cyclophosphamide on alimentation. The animals were randomized into three study groups: control group (group 1), cyclophosphamide-induced HC group (CP-HC; group 2), and cyclophosphamide-induced HC with additional pemirolast treatment group (CP-HC + PEM; group 3). Each of the three groups contained seven 10-week-old female Wistar rats; thus, the experiment initially included 21 animals.
CP-HC model
In 14 animals enrolled in CP-HC with (group 3) or without (group 2) PEM treatment, cyclophosphamide was injected intraperitoneally to produce a model of chemically induced haemorrhagic cystitis with bladder overactivity. In general, depending on CP dose and route of administration, the so-called "acute overactive bladder" model (high single dose) or chronic model (several doses) may be evoked [20, 21] . We conducted our study on the pure CP-HC model caused by cyclophosphamide (Sigma-Aldrich) administered intraperitoneally four times every third day during one week (1st, 3rd, 5th and 7th day) in a dose of 75 mg/kg body weight. Two animals died before the reception of the last CP dose, thus ultimately 12 CP-HC rats were studied. These animals were divided into two groups containing six rats each, one without the concurrent pemirolast treatment (group 2; CP-HC model) and the other with PEM additional treatment (group 3, CP-HC + PEM). In CP-HC subjects, we observed progressive haematuria, which appeared in all remaining CP-HC animals after the last CP dose. Moreover, progressive body weight loss was noted in this group; the mean initial body weight was 189.7 ±10.1 g, which decreased to 157.0 ± 16.1g.
CP-HC + PEM group
Six CP-HC rats were additionally given pemirolast potassium intraperitoneally two hours after the CP dose. The crystalline form of pemirolast potassium was obtained from Sigma Aldrich. After dissolving in water, PEM was administered at a dose of 3 mg/kg of body weight. We employed this dose based on the literature, which suggests a wide range of PEM dosages (1-10 mg/kg body weight) and variable routes (p.o./i.p.) of administration [22, 23] . Our experiment was conducted in accordance with the study by Gohda et al. [24] , who revealed the efficacy of pemirolast at 3 mg/kg intraperitoneally in glomerulonephritis. The animals given PEM as an additional treatment were in better general condition as compared to those in the CP-HC treatment group; however, we also observed a progressive loss of body weight in this group (mean initial body weight: 189.7 ±10.1 g, mean final body weight: 126.5 ± 13.8g). After the last CP/PEM dose, haematuria was noted in two subjects from this group.
Control group
The animals received intraperitoneal injections containing saline solution in volumes similar to those administered to CP-HC rats; the injections were administered every third day during one week. HRV recordings were performed on the 8th day of the experiment.
Procedures associated with assessed parameters:
HRV studies
HRV is the temporary variation in R-R intervals observed on ECG recording and modulated by autonomic influences. It can be analysed in both time and spectral (frequency) domain [25] . According to the study protocol, ECG recordings were performed in each animal on the 8 th day (after last CP, PEM, or saline dose) during 20-minute rest periods under urethane anaesthesia (1200 mg/kg body weight; Sigma-Aldrich). This anaesthetic agent was chosen on the basis of literature reports suggesting a proportional (up to the applied dose) impact on tonic activity of both the sympathetic and parasympathetic ANS and a relatively small influence on cardiac reflexes [26, 27] . Before the study, the abdominal fur of the rats was removed, and the skin was polished with erosive paste and covered with ECG gel. We used paediatrics standard Ag/ AgCl external electrodes (EK-S30 PSG Sorimex) and the Polygram ADInstruments system for ECG recordings and HRV analysis. During the recordings, the rats were kept under heating lamps to prevent a reduction in body temperature, which may influence ANS activity.
After the termination of the ECG recording and extrasinusal extopics elimination, HRV analysis was performed. Standard spectral (frequency), TP (Total Power), VLF (Very Low Frequency), LF (Low Frequency), and HF (High Frequency), all in [ms*ms], as well as normalized nLF and nHF in [n.u.], were calculated. The frequency range for respective spectral components was set at 0.18<VLF<0.28<LF<0.78<HF<3, and commonly accepted interpretation criteria were used. Results are presented as mean values ± SD.
Urinary bladder assessment
After ECG recording, the animals were euthanized by a pentobarbital (Morbital, Biowet, Puławy) overdose (100 mg/kg of body weight). Bladders were collected in both CP-HC and CP-HC + PEM rats, as well as in the controls. We carefully collected bladders with small proximal urethras to make a gross visual assessment of the inflammatory changes. After gentle urine evacuation, the bladders were dried on the gauze, and the samples were weighed to establish bladder wet weight. According to the literature, bladder wet weight is an indirect parameter reflecting intensification of cystitis and oedema [28] [29] [30] . Accordingly, serum biochemical markers were not measured, as we relied on the macroscopic assessment of the bladders that is well established in literature. The ratio of bladder wet weight to final body weight was calculated to express bladder weight independently of individual differences between the rats. The statistical analysis of obtained results compared control (1) to both study groups (2 and 3) with the parametric Fischer-Snedecor test with α=0.05. The final results and statistical analysis are given in Table 1 .
In CP-HC animals, bladders displayed macroscopic inflammatory changes (urinary bladders were red and swollen). Moreover, intra-bladder haematomas were present in CP-HC animals. Histological examination revealed less pronounced inflammatory changes in the rats treated with pemirolast. On visual inspection, the control rats had normal bladders.
Statistical analysis
The statistical assessment of the results obtained in paired groups (CP-HC vs. control and CP-HC+PEM vs. control and and CP-HC vs. CP-HC + PEM) was performed after the results were expressed as values according to the parametric Fischer-Snedecor test with α=0.05. The expression of the values of spectral parameters in the form of natural logarithms resulted from the lack of their normal distribution. We verified the null hypothesis of equality of the parameters' variations in the two populations versus the alternative hypothesis of their inequality (the presence of statistically significant differences).
Results
Animals' weight
All study animals had a similar initial weight, 192.9 ± 4.9 g in the controls (group 1) and 189.7 ± 10.1 g in the rats randomized into groups 2 (CP-treated) and 3 (CP + pemirolast treated). At the end of the experiment (three weeks; 14 days of acclimatisation and one week of oxazaphosphorine/saline/pemirolast administration), there was a difference between the final body weight in individual groups. An increase in final body weight was observed in control rats (approximately 53%; from 192.9 g to 295.5 g). However, in the two remaining groups we noticed a progressive loss of body weight, which was more pronounced in CP-HC rats with additional pemirolast treatment (mean approximately 33.3%; from 189.7 g to 126.5 g); CP-only treated animals displayed a smaller decrease in body weight (about 17.2%; from 189.7 g to 157.0 g). The cause of body weight loss in both oxazaphosphorine-treated groups was the deterioration in their general condition, together with observed diminished food intake as compared to the controls. The stress incurred as a result of double injection (CP and PEM two hours later) may constitute a possible explanation of the larger body weight decrease in CP-HC+PEM animals (group 3).
Bladder wet weight in study groups
Bladder wet weight did not differ significantly in all groups, but CP-HC rats achieved the highest value with regard to this parameter. The ratio of bladder wet weight to final body weight was lowest in control animals, elevated in CP-treated animals, and highest in the pemirolast-treated group. This finding reflects more intensified inflammatory changes and oedema in bladder tissue in all animals receiving CP (groups 2 and 3). However, it should be noted that inferring severe inflammatory changes in the CP-HC+PEM group based on the ratio of the largest bladder wet weight to final body weight can be misleading, because the relative increase in bladder wet weight may be overestimated in association with the smallest final body weight observed in this group. Thus, the bladder wet weight, as a basic parameter, should be considered rather as a marker reflecting macroscopic inflammatory changes.
The detailed description of the results is shown in Table 1 .
HRV time-domain parameters
In all groups, most of calculated differences in timedomain HRV parameters were insignificant. The control rats had the longest NN intervals and the square root of the mean squared difference of successive normalnormal (N-N) intervals (rMSSD) as compared to the animals treated with cyclophosphamide. The mean NN interval was the highest in pemirolast-treated rats. The only difference relating to control and CP-HC groups was related to rMSSD, which was higher in control animals.
HRV spectral-domain parameters
Among the groups, the spectral (frequency) HRV analysis showed numerous statistically significant differences.
In general, similar to our previous study [12] , we found a decrease in non-normalized HRV spectral parameters in cyclophosphamide-treated rats. The main parameters, LF and HF, had the lowest values in group 3. Moreover, pemirolast-treated CP-HC rats (group 3) displayed the highest percentage for a VLF component and the lowest percentage for HF. Although the numerical value of VLF was almost the same as in the control group, it was the largest part of the HRV spectrum in pemirolast-treated rats. We also demonstrated a complete dissimilarity in the relationships between standardized spectral parameters, which, contrary to the control and CP-HC groups with nHF-stated majority, were opposite in regard to nLF predominance. Pemirolasttreated rats also displayed the highest LF/HF ratio.
The detailed results are shown in Table 2 . 
Discussion
The main findings of our study include: 1.As in our prior work, in rats with cystitis due to CP treatment, we have again demonstrated a decreasing trend of overall autonomic activity, together with the predominance of VLF power over the remaining non-normalized components of HRV. In our opinion, autonomic impairment following the administration of CP is reflected by a fall in total autonomic tension with relative VLF functional predominance, which is due to systemic (including cardiovascular) stress resulted from the cytotoxic action of CP.
2. Pemirolast treatment did not result in an improvement in the value of total HRV power or in key nonnormalized HRV components (LF, HF), which suggests the maintenance of low global ANS activity in CP-HC + PEM rats. VLF power reached almost the same value as that recorded in control rats; however, VLF in this group comprised as much as 82% of total HRV power, and similar to the CP-HC group, this HRV component predominated in total power. Moreover, CP-HC rats treated with pemirolast displayed a different disproportion of normalized spectral components as compared to both control and CP-HC animals, with the balance between nLF and nHF shifted towards nLF. This finding, together with relatively high VLF tension, indicates that pemirolast caused the functional rearrangement in the activity of ANS branches with marked sympathetic overdrive.
Normal sinus heart rate variability results from the dynamic autonomic interplay that regulates the instantaneous heart rate. The study of heart rate variability, which reflects the impact of ANS on heart rate, is currently considered to be the best non-invasive tool for assessing ANS activity. The parasympathetic fibers prolong the interbeat interval (measured in milliseconds [ms]), whereas the sympathetic fibers shorten this interval. These temporary fluctuations are expressed by mean NN [ms], main HRV parameter, and a number of derived statistical parameters, and they constitute the time-domain HRV analysis [31, 32] . Moreover, additional insight into the nature of heart rate fluctuations may be gained by analysing the fluctuations in the frequency domain, which is based on the fast Fourier transformation method. The frequency (spectral) HRV analysis provides information of how power (variability) is distributed as a function of frequency and enables a clinical interpretation of obtained results. Numerous physiological studies have shown that parasympathetic influences predominate at the frequency range 0.15-0.4 Hz (HF; High Frequency component) of the heart rate power spectrum, whereas the sympathetic influences prevail at approximately 0.04-0.15Hz (LF; Low Frequency component). However, vagal blockade or excitation may also produce some modification in the power of the LF component. Therefore, it is commonly agreed that the high frequency band represents parasympathetic influences, while the low (LF) has a mixed, sympathetic and parasympathetic character. It is also possible to express pure sympathetic or parasympathetic activity as normalized nLF or nHF, respectively, calculated by expressing the power of relevant components (LF or HF) in relation to total HRV power, excluding VLF component power [25, 33, 34] . The short-term HRV spectrum also contains very low frequencies (VLF, 0.0033-0.04 Hz); however, it is not possible to ascertain whether increased sympathetic or parasympathetic activity contributes to VLF power because the physiological background involved in the development of this HRV component remains unknown. VLF is thought to reflect circadian and neuroendocrine rhythms, thermoregulatory processes, renin-angiotensin system activity, and hemodynamic feedback delays. Although, the meaning of VLF is still not clearly understood, most HRV experts recommend considering this component as a marker of sympathetic activity, also reflecting general systemic stress [25] . Conversely, there is a difference of opinions regarding VLF as a marker of parasympathetic stimulation. According to Taylor et al. [35] , VLF depends primarily on the presence of parasympathetic outflow. These authors also showed that atropine almost completely abolished VLF power and other spectral components, suggesting that HRV present in the VLF band is driven by parasympathetic modulation. Silva Soares et al. [36] demonstrated experimentally that stimulation with pyridostigmine (reversible cholinesterase inhibitor) produced a strong increase in VLF. Therefore, the prognostic value of VLF oscillations may also derive from the fundamental importance of parasympathetic mechanisms. Based on these guidelines for HRV interpretation, we assessed our results as explained at the beginning of the "Discussion" section.
We conclude that pemirolast failed to improve global autonomic tension and caused an autonomic imbalance opposite to the one observed in the CP-HC group without accompanying pemirolast treatment, which manifested as nLF and VLF augmentation with high sympathetic activity. Therefore, despite the potential anti-inflammatory properties of pemirolast as a consequence of inhibiting pro-inflammatory neuropeptides [18] , this drug was ineffective in improving the function of ANS. It seems that CP-induced cystitis is not so much attenuated as it is sustained by pemirolast-evoked autonomic disturbances. Numerous studies suggest a prominent role of the autonomic nervous system in regulating inflammation; the immune system and ANS interact via autonomic pathways and continuously modulate each other. According to most researchers, high parasympathetic outflow and increased HRV are associated with anti-inflammatory activity via inhibition of macrophage activation and subsequent release of pro-inflammatory cytokines and neuropeptides from these cells [37] . This statement is consistent with the identification of the cholinergic anti-inflammatory pathway that has advanced our understanding of the neural regulation of the inflammatory process. The immunomodulatory role is enacted by acetylcholine released from parasympathetic efferents; this molecule interacts with α-bungarotoxin-sensitive nicotinic receptors on tissue macrophages, which inhibits the release of tumor necrosis factor α (TNF-α), high-mobility group box 1 (HMGB1), and other cytokines [37] [38] [39] . We did not find parasympathetic excitation after pemirolast treatment in rats with CP-induced cystitis. Therefore, the diminished vagal tone may implicate the lack of the cholinergic antiinflammatory reflex and, consequently, a poor outcome related to the course of the inflammation.
The role of the sympathetic nervous system in immunomodulation is unambiguous and supported by evidence showing that the sympathetic branch mediates both pro-inflammatory and anti-inflammatory responses. According to a number of researchers [40] [41] [42] , activation of the sympathetic nervous system exacerbates local and general pro-inflammatory reactions. On the other hand, several studies have indicated that sympathetic stimulation has an inhibitory effect on the inflammatory process [43] [44] [45] . We obtained somewhat conflicting results illustrating sympathetic activity. The decrease in LF may be considered as a marker of diminished sympathetic activity; however, LF is thought to reflect the tone of both branches of ANS, especially if a fall in LF is evaluated, together with a simultaneous decrease in HF. Thus, in our opinion, the observed drop in both non-normalized HRV components, LF and HF, should be treated as evidence of the withdrawal of parasympathetic function. Moreover, in CP-HC+PEM rats, we showed a clear nLF increment with nHF decline as compared to the animals without pemirolast treatment. Again, these findings support sympathetic predominance and parasympathetic withdrawal. Nonetheless, we also demonstrated a relative increase in VLF percentage in the total HRV spectrum in the pemirolast-treated CP-HC group. Although the mechanisms underlying VLF origin are still not fully understood, there is evidence that this HRV component may also be implicated in sympathetic-dependent mechanisms [25] . This observation constitutes an additional argument for ANS impairment with sympathetic overactivation.
In conclusion, our results in CP-HC + PEM rats show an nLF and VLF increase together with an LF, HF, and nHF decline, which we believe suggests increased sympathetic and diminished parasympathetic activity. The sympathetic overdrive observed during pemirolast treatment may be responsible for maintaining CPevoked cystitis. Thus, this antihistaminic agent, despite its additional inhibitory effect related to the release of neuropeptides, seems to be ineffective in attenuating CP-induced cystitis.
Footnotes
List of the most important abbreviations used in the body text (in alphabetical order) ADR -adverse drug reactions ANS -autonomic nervous system CP -cyclophosphamide CP-HC -cyclophosphamide induced HC HC -haemorrhagic cystitis HF -high frequency (a HRV spectrum component) HRV -heart rate variability IF -ifosfamide LF -low frequency (a HRV spectrum component) nHF -normalized HF nLF -normalized LF PEM -pemirolast potassium rMSSD -the square root of the mean squared difference of successive normal-normal (N-N) intervals VLF -very low frequency (a HRV spectrum component)
